TEVA-A Pharma Stock to Watch

September 11, 2023

Mish's Daily

By Mish Schneider

Every week, I am invited on Business First AM with Angela Miles to discuss the market and give a stock pick.

This week, I covered TEVA, a stock I have talked about a few times and one, full disclosure, we are positioned in.

First, about the company:

Teva Pharmaceuticals is an international pharmaceutical company headquartered in Israel.

Founded in 1901, Teva is one of the world's largest generic drug manufacturers.

The company specializes in the development, production, and marketing of a wide range of generic and specialty pharmaceutical products.

Teva's generic drugs are typically less expensive alternatives to brand-name medications, which can help make healthcare more affordable for patients and healthcare systems.

In addition to generics, Teva also develops and manufactures specialty pharmaceuticals, including drugs for conditions such as multiple sclerosis, respiratory diseases, and central nervous system disorders.

Challenges legally resolved:

The company has faced its share of challenges and controversies, including legal disputes related to generic drug pricing and allegations of anticompetitive behavior.

However, one big development TEVA reached a deferred prosecution agreement (DPA) with the U.S. Department of Justice (DOJ) to settle the criminal price-fixing charges brought against Teva in 2020. Teva will pay a fine of $225 million over five years, with $22.5 million due each year from 2024 through 2027, and $135 million due in 2028.

The bad news is that this will impact on their bottom line.

The good news is that the case is settled and done with.

The chart is fascinating.

The resistance at 10.00 is clear on the daily chart.

TEVA is one of the few instruments that has handily cleared its July 6-month calendar range high (green horizontal line).

The 50 daily moving average is about to cross or golden cross the 200-DMA and enter a bullish phase.

Since the earnings gap early August, price has consolidated.

Our Leadership indicator show TEVA beginning to outperform the SPY.

Our Real Motion indicator already in a bullish phase is not quite at the early August high in momentum so that is why we are waiting for a clearance of the price resistance at 10.00

This is for educational purposes only. Trading comes with risk.


If you find it difficult to execute the MarketGauge strategies or would like to explore how we can do it for you, please email Ben Scheibe at [email protected], our Head of Institutional Sales. Cell 612-518-2482

For more detailed trading information about our blended models, tools, and trader education courses, contact Rob Quinn, our Chief Strategy Consultant, to learn more.

Get your copy of
Plant Your Money Tree: A Guide to Growing Your Wealth

Grow Your Wealth Today and Plant Your Money Tree!

"I grew my money tree and so can you!"- Mish Schneider

Mish in the Media - All clips here

CNBC Asia Partial clip-Inflation 09-07-23

Singapore Radio 09-07-23

CMC Markets Daytrading Oil, Gas, Gold, Silver, Dollar Pairs 09-06-23

Business First AM Worst Trade Best Trade 09-05-23


Coming Up:

September 12 BNN Bloomberg

September 12 Charting Forward StockchartsTV

September 12 Making Money with Charles Payne Fox

September 13 Futures Edge Podcast with Bob Iaccino

September 13 Investing with IBD Podcast

October 29-31 The Money Show


ETF Summary

S&P 500 (SPY) 440 support 458 resistance

Russell 2000 (IWM) 185 pivotal

Dow (DIA) 347 pivotal

Nasdaq (QQQ) 363 support and over 375 looks better

Regional banks (KRE) Another modern family member struggling here under 44

Semiconductors (SMH) 150-161 range to watch

Transportation (IYT) Needs to get back over 247 to look healthier

Biotechnology (IBB) Compression between 124-130

Retail (XRT) 62.90 the July calendar range low broke down-along with IYT-2 negative signs

Improve Your Returns With 'Mish's Daily'

Michele 'Mish' Schneider

Every day you'll be prepared to trade with:

  • Unique insight into the health and future trends in markets
  • Key trading levels for major ETFs
  • The 'Modern Family' advantage
  • Actionable trading ideas in stocks and ETFs across all asset classes
Subscribe Now!